Abstract: In some embodiments, the present disclosure provides a method for fabricating a three-dimensional artificial cardiac patch construct. In some embodiments, such method includes the steps of coating a substrate with an organic polymer; allowing the organic polymer coating to air dry; mounting anchors on the organic polymer coating; and sterilizing the organic polymer coating and the anchors. In further embodiments, the method includes the steps of forming a biodegradable gel-based support scaffold on top of the organic polymer coating and seeding the biodegradable gel-based support scaffold with neonatal cardiac cells. In yet further embodiments, the method comprises culturing the neonatal cardiac cells in vitro to form a real cardiac layer, under culture conditions that are suitable for the cells to self-organize into a monolayer and detach from the substrate to form the three-dimensional cardiac patch.

Abstract: According to some embodiments of the invention, an electro-optic device includes a first plurality of electrodes, a second plurality of electrodes spaced apart from the first plurality of electrodes, and an active layer between the first plurality of electrodes and the second plurality of electrodes. The active layer comprises a plurality of electromagnetic resonators. At least one of the first plurality of electrodes and the second plurality of electrodes is at least partially transparent to light of a spectral range that can be absorbed or emitted by the plurality of electromagnetic resonators. The first and second plurality of electrodes are electrically connected to the plurality of electromagnetic resonators. The spacings between at least a selected pair of the plurality of electromagnetic resonators is provided such that a real component of a coupling coefficient between the selected pair of the plurality of electromagnetic resonators is substantially canceled.

Abstract: Externally-strained devices such as LED and FET structures as discussed herein may have strain applied before or during their being coupled to a housing or packaging substrate. The packaging substrate may also be strained prior to receiving the structure. The strain on the devices enables modulation of light intensity, color, and electrical currents in some embodiments, and in alternate embodiments, enables a fixed strain to be induced and maintained in the structures.

Abstract: The invention relates to a solvent-free green ammoximation process based on membrane distribution with a procedure as: adding TS-1 catalyst and ketone into a reactor in advance; setting the stirring speed and reaction temperature; after reaching the set temperature, adding a certain amount of ammonia and hydrogen peroxide into a reaction solution, wherein the hydrogen peroxide is fed in a way of using membrane as a distributor, the ammonia is fed in a continuous or semi-continuous manner; oxime is produced upon the reaction. The advantages of the invention include the mild reaction conditions, high reacting efficiency, simple operation and environmentally-friendly process. And there is no need to add any solvent during the reaction process. During the ammoximation reaction, both the conversion rate of the ketone and the selectivity of the oxime can be over 98.0%.

Abstract: Battery electrolytes comprising: (a) a solvent suitable for use in a battery electrolyte such as an organic liquid solvent or an ionic liquid; (b) a lithium ion or sodium ion salt suitable for use in a battery electrolyte; and (c) a dispersion of nanoparticles of carbon, metal or metalloid oxides or hydroxides, carbides, nitrides, sulfides, graphene or MXene particles; or a combination thereof. The present invention is also directed to battery cells and batteries comprising these electrolytes and devices comprising these battery cells and batteries.

Abstract: Compositions and methods for inhibition UVB-irradiation damage by targeting constitutive nitric oxide synthases (cNOS), including endothelial NOS (eNOS) and neuronal NOS (nNOS) are described.

Abstract: According to one or more embodiments, a mesoporous zeolite may included a microporous framework that includes a plurality of micropores having diameters of less than or equal to 2 nm, and a plurality of mesopores having diameters of greater than 2 nm and less than or equal to 50 nm. The mesoporous zeolite may included an aluminosilicate material, a titanosilicate material, or a pure silicate material. The mesoporous zeolite may included a surface area of greater than 350 m2/g and a pore volume of greater than 0.3 cm3/g.

Abstract: Formulations for treating burns and burn wound healing comprising a Granzyme B inhibitor and a pharmaceutically acceptable carrier, and methods for treating burns and for burn wound healing using the formulations.

Abstract: The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.

Abstract: There is provided a composition including a 3-bromo-4,5-dihydroxybenzaldehyde (BDB) for protecting human skin keratinocyte from ultraviolet, in which the BDB has a photo-protective effect against cell damage caused by ultraviolet in human HaCaT skin keratinocyte, activity of removing a free radical, and ultraviolet absorption activity, and inhibits formations of lipid peroxidation and protein carbonyl, inhibits DNA damage, protects a cell, and thereby exhibits cell protective activity. Thus, the BDB decreases apoptosis induced by ultraviolet, and then protect a cell to recover cell viability.

Abstract: In various embodiments, a method for determining at least one pore-related parameter of a porous structure is provided. The method includes supplying a volatile liquid into a chamber. The method also includes coating a first surface of the porous structure with an evaporation preventing substance. The method further includes placing the coated porous structure within the chamber. The method additionally includes determining an effective mass of the chamber over a period of time. The method also includes determining the at least one pore-related parameter of an uncoated second surface of the coated porous structure based on the effective mass determined. The second surface of the porous structure is opposite the first surface of the porous structure.

Abstract: Disclosed are methods and compositions for treating a subject having a neurological disorder such as major depressive disorder (MDD). The methods and compositions may be utilized in order to inhibit trafficking of hyperpolarization-activated cyclic nucleotide gated (HCN) channels or subunits thereof, in some embodiments, by inhibiting an interaction between the HCN channels or the subunits thereof and an auxiliary protein or a chaperone protein for the HCN channels or the subunits thereof such as tetratricopeptide repeat (TPR)-containing Rab8b interacting (TRIP8b) protein or a variant thereof. The HCN channels of the disclosed methods may comprise, for example, HCN1 subunits, HCN2 subunits, or a combination thereof. In the disclosed methods, trafficking of the HCN channels or subunits preferably results in inhibiting distal dendritic enrichment of HCN1 and HCN2 in pyramidal neurons of hippocampal area CA1.

Abstract: Provided are methods for disrupting biofilms and/or preventing the formation of biofilms. Further provided are random-sequence peptide mixtures for use in disrupting bacterial biofilms. The random-sequence peptides include hydrophobic and/or cationic amino acids, and the ratio of the total hydrophobic and cationic amino acids in the mixture is predefined.

Abstract: An arm supporting exoskeleton comprises a shoulder base coupled to an arm link mechanism. The arm link mechanism comprises a proximal link and a distal link configured to rotate relative to each other about a rotating joint; at least one arm-coupler adapted to couple a user's arm to the distal link; a tensile force generator coupled to the proximal link and the distal link, and providing a torque to flex the distal link relative to the proximal link; and a protrusion located substantially at the rotating joint. When the distal link extends past a toggle angle, the protrusion constrains the tensile force generator, and the torque provided by the tensile force generator remains substantially small. When the protrusion does not constrain the tensile force generator, the torque tends to flex the distal link relative to the proximal link, thereby reducing human shoulder forces and torques required to raise the arm.

Abstract: Embodiments of the present invention may be generally related to methods, devices, and systems which measure a gravitational field. The methods and devices may utilize an interferometer to measure tilt of a pendulum, where the tilt of the pendulum is due to a gravitational force associated with a target object. In some embodiments, the interferometer may be a displaced, even parity, Sagnac interferometer. Additionally, the interferometer may be operated in the inverse weak value domain. In some embodiments, the pendulum and interferometric readout may measure relative gravitational fields that are transverse to Earth's gravitational field. In at least some embodiments, methods and devices may have shot noise limited sensitivity sufficient to detect one kilogram 25 meters away and may have a 1 nGal resolution after mere seconds of integration. Embodiments disclosed may be used to gravitationally map density fluctuations in a target object, including the human body.

Abstract: One aspect of the invention provides a method of sequentially inducing macrophage conversion in a wound. The method includes: (a) administering IL-4 to induce conversion of a first population of wound macrophages in the wound to M2A macrophages; and then (b) administering IL-10, dexamethasone, or a dexamethasone analog to induce conversion of a second population of wound macrophages in the wound to M2C macrophages.

Abstract: The present invention includes methods and compositions for elimination of polyoma viruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyoma-virus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyoma virus.

Abstract: Provided are astexin-1, astexin-2 and astexin-3 lasso peptides, which are based on sequences identified in Asticcacaulis excentricus, and methods of making and using same. Astexin-1 is highly polar, in contrast to many lasso peptides that are primarily hydrophobic, and has modest antimicrobial activity against Caulobacter crescentus, a bacterium related to Asticcacaulis excentricus. The solution structure of astexin-1 was determined, revealing a unique topology that is stabilized by hydrogen bonding between segments of the peptide. Astexins-2 and -3 are intracellular lasso peptides.

Abstract: A photonic conversion device is provided, comprising a photoactive layer, a dielectric layer, a porous conductor layer, and an electron transport layer in contact with the porous conductor layer. A light emitting device may be in contact with the electron transport layer, forming a conversion device with gain. A method of manufacturing a photonic conversion device may also be provided, comprising forming a photoactive layer, forming a dielectric layer over the photoactive layer, and depositing a conductor layer in contact with the dielectric layer, wherein one or more regions of the dielectric layer are masked during deposition such that the conductor layer includes a plurality of pores that extend through the conductor layer.

Abstract: An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining region (CDR) CDR-L3 and the heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3, with the amino acid sequences of said CDRs comprising one or more of the sequences set forth below: CDR-L3; selected from any one of SEQ ID NOs: 123, 126-130, 142, 148 or 149; CDR-H1: SEQ ID NOs: 121 or 124; CDR-H2; SEQ ID NOs: 122 or 125; and/or CDR-H3: selected from any one of SEQ ID NOs: 196-226.